139 related articles for article (PubMed ID: 25614435)
1. Reply: could late enhancement and need for permanent pacemaker implantation in patients undergoing TAVR be explained by undiagnosed transthyretin cardiac amyloidosis?
Siontis GC; Windecker S
J Am Coll Cardiol; 2015 Jan; 65(3):313. PubMed ID: 25614435
[No Abstract] [Full Text] [Related]
2. Reply: could late enhancement and need for permanent pacemaker implantation in patients undergoing TAVR be explained by undiagnosed transthyretin cardiac amyloidosis?
Kim WK; Rolf A; Möllmann H
J Am Coll Cardiol; 2015 Jan; 65(3):312-3. PubMed ID: 25614434
[No Abstract] [Full Text] [Related]
3. Could late enhancement and need for permanent pacemaker implantation in patients undergoing TAVR be explained by undiagnosed transthyretin cardiac amyloidosis?
Castaño A; Bokhari S; Maurer MS
J Am Coll Cardiol; 2015 Jan; 65(3):311-2. PubMed ID: 25614433
[No Abstract] [Full Text] [Related]
4. Time Course of Common Clinical Manifestations in Patients with Transthyretin Cardiac Amyloidosis: Delay From Symptom Onset to Diagnosis.
Papoutsidakis N; Miller EJ; Rodonski A; Jacoby D
J Card Fail; 2018 Feb; 24(2):131-133. PubMed ID: 29305186
[No Abstract] [Full Text] [Related]
5. Comparison between (99m)Tc-diphosphonate imaging and MRI with late gadolinium enhancement in evaluating cardiac involvement in patients with transthyretin familial amyloid polyneuropathy.
Minutoli F; Di Bella G; Mazzeo A; Donato R; Russo M; Scribano E; Baldari S
AJR Am J Roentgenol; 2013 Mar; 200(3):W256-65. PubMed ID: 23436870
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis. Progress and Hope.
González-López E; López-Sainz Á; Garcia-Pavia P
Rev Esp Cardiol (Engl Ed); 2017 Nov; 70(11):991-1004. PubMed ID: 28870641
[TBL] [Abstract][Full Text] [Related]
7. Extracellular Volume Detects Amyloidotic Cardiomyopathy and Correlates With Neurological Impairment in Transthyretin-familial Amyloidosis.
Gallego-Delgado M; González-López E; Muñoz-Beamud F; Buades J; Galán L; Muñoz-Blanco JL; Sánchez-González J; Ibáñez B; Mirelis JG; García-Pavía P
Rev Esp Cardiol (Engl Ed); 2016 Oct; 69(10):923-930. PubMed ID: 27291669
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis.
Gertz MA; Benson MD; Dyck PJ; Grogan M; Coelho T; Cruz M; Berk JL; Plante-Bordeneuve V; Schmidt HHJ; Merlini G
J Am Coll Cardiol; 2015 Dec; 66(21):2451-2466. PubMed ID: 26610878
[TBL] [Abstract][Full Text] [Related]
9. Days alive and outside of hospital from diagnosis of transthyretin vs. light chain cardiac amyloidosis.
Rubin J; Teruya S; Helmke S; De Los Santos J; Alvarez J; Maurer MS
Amyloid; 2019; 26(sup1):4-5. PubMed ID: 31343342
[No Abstract] [Full Text] [Related]
10. A representative case of hereditary transthyretin amyloidosis complicated by intramyocardial hemorrhage.
Yagi H; Amiya E; Shintani Y; Nitta D; Numakura S; Hosoya Y; Watanabe M; Fukayama M; Komuro I
Amyloid; 2015 Mar; 22(1):70-2. PubMed ID: 25427692
[No Abstract] [Full Text] [Related]
11. Diagnosis of cardiac transthyretin amyloidosis based on multimodality imaging.
Dahlem K; Michels G; Kobe C; Bunck AC; Ten Freyhaus H; Pfister R
Clin Res Cardiol; 2017 Jun; 106(6):471-473. PubMed ID: 28303323
[No Abstract] [Full Text] [Related]
12. Acute cardiac failure secondary to senile systemic amyloidosis.
Bodard Q; Roca F; Dilly B; Laurent D; Chassagne P
Age Ageing; 2016 Nov; 45(6):908-909. PubMed ID: 27103598
[TBL] [Abstract][Full Text] [Related]
13. Cardiac amyloidosis: updates in diagnosis and management.
Mohty D; Damy T; Cosnay P; Echahidi N; Casset-Senon D; Virot P; Jaccard A
Arch Cardiovasc Dis; 2013 Oct; 106(10):528-40. PubMed ID: 24070600
[TBL] [Abstract][Full Text] [Related]
14. [State-of-the-art review on the non-invasive diagnosis approaches of patients with transthyretin cardiac amyloidosis].
He S; Tian Z; Zhang SY
Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr; 48(4):276-279. PubMed ID: 32370477
[TBL] [Abstract][Full Text] [Related]
15. Wild-Type Transthyretin Cardiac Amyloidosis: Novel Insights From Advanced Imaging.
Narotsky DL; Castano A; Weinsaft JW; Bokhari S; Maurer MS
Can J Cardiol; 2016 Sep; 32(9):1166.e1-1166.e10. PubMed ID: 27568874
[TBL] [Abstract][Full Text] [Related]
16. CMR and amyloid cardiomyopathy: are we getting closer to the biology?
Kwong RY; Jerosch-Herold M
JACC Cardiovasc Imaging; 2014 Feb; 7(2):166-8. PubMed ID: 24524743
[No Abstract] [Full Text] [Related]
17. Unmasking Early Wild-Type Transthyretin Amyloidosis Cardiomyopathy in a Patient With Refractory Atrial Fibrillation and Unremarkable Cardiac Imaging.
Varedi D; Kovacsovics T; Downs Kelly E; Abraham J; Cowley J; Barrell K; Revelo MP; Stehlik J; Drakos S; Marrouche N; Wilson B; Swanson EA; Fang J; Nativi-Nicolau J
Circ Heart Fail; 2018 Jul; 11(7):e004812. PubMed ID: 29921704
[No Abstract] [Full Text] [Related]
18. The serum level of plasmin-alpha2 plasmin inhibitor complex (PIC) is useful for differentiating cardiac light chain amyloidosis from transthyretin amyloidosis.
Shimazaki C; Matsui-Maegawa S; Kimoto-Matsumura Y; Ota-Kuwabara S; Ide D; Fuchida SI; Hatsuse M
Br J Haematol; 2023 Sep; 202(6):1209-1212. PubMed ID: 37424146
[No Abstract] [Full Text] [Related]
19. Cost-effectiveness of transthyretin cardiac amyloidosis screening and treatment: A Dilemma for the clinician.
Castiglione V; Aimo A; Vergaro G
Int J Cardiol; 2024 May; 402():131855. PubMed ID: 38360098
[No Abstract] [Full Text] [Related]
20. Disparities, Uncertainties, and Societal Cost: Precision Medicine and Transthyretin Amyloidosis.
Hauptman PJ; Wall JS; Maurer MS
Am J Med; 2020 Aug; 133(8):892-894. PubMed ID: 32268147
[No Abstract] [Full Text] [Related]
[Next] [New Search]
